Inflammation is a reaction our bodies have to any infection. People living with HIV can have increased inflammation in their organs even if their HIV is well controlled and the viral load is undetectable. Chronic HIV infection has been shown to increase the incidence, complications, and death from heart disease. The purpose of this study (A5415) is to see if an oral drug called Cenicriviroc can lower inflammation in blood vessels and possibly prevent heart related complications in people with HIV. Its effect on lowering inflammation in blood vessels will be measured by looking at the aorta (the main artery in your body) using a test called a PET-CT scan.
Eligibility:
- ≥ 45 years of age
- HIV positive
- On continuous HIV treatment for at least 48 weeks
- Undetectable viral load for at least 48 weeks
- T-cell count >200 cells/mm3
- At least one risk factor for heart disease
For more information about A5415, please contact our study team at 310-843-2015 or CAREOUTREACH@mednet.ucla.edu .
